Praxis Precision Medicines (PRAX) Financials

$33.79 +3.96 (+13.28%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$33.84 +0.05 (+0.16%)

As of 04/17/2025 06:19 PM Eastern

Annual Income Statements for Praxis Precision Medicines

This table shows Praxis Precision Medicines' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-214	-123	-183
Consolidated Net Income / (Loss)	-214	-123	-183
Net Income / (Loss) Continuing Operations	-214	-123	-183
Total Pre-Tax Income	-214	-123	-183
Total Operating Income	-215	-126	-200
Total Gross Profit	0.00	2.45	8.55
Total Revenue	0.00	2.45	8.55
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	215	129	209
Selling, General & Admin Expense	60	42	56
Research & Development Expense	155	87	152
Total Other Income / (Expense), net	0.96	3.10	17
Other Income / (Expense), net	0.96	3.10	17
Basic Earnings per Share	($69.65)	($18.69)	($10.21)
Weighted Average Basic Shares Outstanding	3.07M	6.59M	17.91M
Diluted Earnings per Share	($69.65)	($18.69)	($10.21)
Weighted Average Diluted Shares Outstanding	3.07M	6.59M	17.91M
Weighted Average Basic & Diluted Shares Outstanding	52.39M	13.24M	20.16M

This table shows Praxis Precision Medicines' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-44	-41	-37	-34	-25	-27	-40	-33	-52	-59
Consolidated Net Income / (Loss)	-44	-41	-37	-34	-25	-27	-40	-33	-52	-59
Net Income / (Loss) Continuing Operations	-44	-41	-37	-34	-25	-27	-40	-33	-52	-59
Total Pre-Tax Income	-44	-41	-37	-34	-25	-27	-40	-33	-52	-59
Total Operating Income	-44	-41	-38	-35	-26	-28	-42	-37	-57	-64
Total Gross Profit	0.00	-	0.68	0.78	0.47	0.52	0.43	0.36	0.30	7.46
Total Revenue	0.00	-	0.68	0.78	0.47	0.52	0.43	0.36	0.30	7.46
Total Operating Expenses	44	41	39	36	26	28	42	38	57	71
Selling, General & Admin Expense	14	13	13	10	8.72	9.93	15	11	15	15
Research & Development Expense	30	28	26	26	17	18	27	27	42	56
Total Other Income / (Expense), net	0.35	0.28	0.64	0.65	0.88	0.93	2.33	4.81	4.93	5.28
Other Income / (Expense), net	0.35	0.28	0.64	0.65	0.88	0.93	2.33	4.81	4.93	5.28
Basic Earnings per Share	($0.96)	($13.40)	($10.58)	($7.38)	($2.72)	($4.08)	($2.84)	($1.74)	($2.75)	($3.28)
Weighted Average Basic Shares Outstanding	45.77M	3.07M	3.54M	4.65M	9.04M	6.59M	13.90M	18.82M	18.88M	17.91M
Diluted Earnings per Share	($0.96)	($13.40)	($10.58)	($7.38)	($2.72)	($4.08)	($2.84)	($1.74)	($2.75)	($3.28)
Weighted Average Diluted Shares Outstanding	45.77M	3.07M	3.54M	4.65M	9.04M	6.59M	13.90M	18.82M	18.88M	17.91M
Basic & Diluted Earnings per Share	-	($13.40)	-	-	-	($4.08)	-	-	-	($3.28)
Weighted Average Basic & Diluted Shares Outstanding	47.12M	52.39M	62.10M	128.54M	128.55M	13.24M	17.11M	17.76M	18.64M	20.16M

This table details how cash moves in and out of Praxis Precision Medicines' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	-78	20	134
Net Cash From Operating Activities	-185	-111	-132
Net Cash From Continuing Operating Activities	-185	-111	-132
Net Income / (Loss) Continuing Operations	-214	-123	-183
Consolidated Net Income / (Loss)	-214	-123	-183
Depreciation Expense	0.42	0.43	0.36
Amortization Expense	1.00	0.05	-5.01
Non-Cash Adjustments To Reconcile Net Income	29	26	45
Changes in Operating Assets and Liabilities, net	-1.78	-14	11
Net Cash From Investing Activities	97	39	-248
Net Cash From Continuing Investing Activities	97	39	-248
Purchase of Property, Plant & Equipment	-0.44	-0.05	0.00
Purchase of Investments	-83	0.00	-372
Sale and/or Maturity of Investments	180	39	123
Net Cash From Financing Activities	10	92	514
Net Cash From Continuing Financing Activities	10	92	514
Issuance of Common Equity	11	92	515
Other Financing Activities, net	-0.26	-0.14	-0.31

This table details how cash moves in and out of Praxis Precision Medicines' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	6.40	-0.83	19	43	-23	-20	71	-6.84	24	47
Net Cash From Operating Activities	-45	-29	-33	-31	-23	-24	-21	-27	-28	-56
Net Cash From Continuing Operating Activities	-45	-29	-33	-31	-24	-23	-21	-27	-28	-56
Net Income / (Loss) Continuing Operations	-44	-41	-37	-34	-25	-27	-40	-33	-52	-59
Consolidated Net Income / (Loss)	-44	-41	-37	-34	-25	-27	-40	-33	-52	-59
Depreciation Expense	0.10	0.11	0.11	0.11	0.11	0.11	0.11	0.11	0.09	0.05
Amortization Expense	0.21	0.20	0.05	0.00	-	-	-0.08	-1.53	-2.01	-1.39
Non-Cash Adjustments To Reconcile Net Income	6.92	6.56	7.35	6.42	4.80	7.12	17	6.11	13	8.82
Changes in Operating Assets and Liabilities, net	-8.21	5.50	-3.10	-3.23	-3.92	-3.78	1.47	0.72	14	-4.92
Net Cash From Investing Activities	48	23	34	5.00	-	-0.05	-91	-196	50	-11
Net Cash From Continuing Investing Activities	48	23	34	5.00	-0.05	-	-91	-196	50	-11
Purchase of Investments	-	-	0.00	-	-	-	-91	-199	-12	-69
Sale and/or Maturity of Investments	48	23	34	5.00	-	-	0.00	3.00	62	59
Net Cash From Financing Activities	3.37	5.39	18	70	-	4.13	183	216	1.44	114
Net Cash From Continuing Financing Activities	3.37	5.39	18	70	-	4.13	183	216	1.44	114
Issuance of Common Equity	3.37	5.39	18	70	0.00	4.13	183	216	1.44	114
Other Financing Activities, net	-0.01	-0.01	-0.13	-0.00	-0.00	-0.01	-0.14	-0.01	-0.00	-0.16

This table presents Praxis Precision Medicines' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	115	88	483
Total Current Assets	111	85	404
Cash & Equivalents	62	81	215
Short-Term Investments	39	0.00	177
Prepaid Expenses	10	3.58	12
Plant, Property, & Equipment, net	0.97	0.59	0.23
Total Noncurrent Assets	3.32	2.48	79
Long-Term Investments	-	0.00	77
Other Noncurrent Operating Assets	3.32	2.48	1.55
Total Liabilities & Shareholders' Equity	115	88	483
Total Liabilities	39	18	38
Total Current Liabilities	34	16	38
Accounts Payable	15	5.82	13
Accrued Expenses	16	7.42	24
Current Deferred Revenue	2.82	1.39	0.00
Other Current Liabilities	1.01	1.13	1.26
Total Noncurrent Liabilities	4.68	2.53	0.11
Noncurrent Deferred Revenue	2.18	1.16	0.00
Other Noncurrent Operating Liabilities	2.50	1.37	0.11
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	76	70	445
Total Preferred & Common Equity	76	70	445
Preferred Stock	0.00	0.00	0.00
Total Common Equity	76	70	445
Common Stock	607	724	1,282
Retained Earnings	-531	-654	-837
Accumulated Other Comprehensive Income / (Loss)	-0.17	0.00	0.65

This table presents Praxis Precision Medicines' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	137	98	133	107	250	441	416
Total Current Assets	132	94	130	103	212	357	360
Cash & Equivalents	62	81	124	101	152	145	169
Short-Term Investments	61	4.98	0.00	0.00	55	207	188
Prepaid Expenses	8.57	8.58	5.53	2.24	4.39	4.84	3.02
Plant, Property, & Equipment, net	1.08	0.87	0.76	0.70	0.48	0.37	0.28
Total Noncurrent Assets	3.51	3.12	2.91	2.70	38	84	56
Long-Term Investments	-	-	-	-	36	82	54
Other Noncurrent Operating Assets	3.51	3.12	2.91	2.70	2.26	2.03	1.79
Total Liabilities & Shareholders' Equity	137	98	133	107	250	441	416
Total Liabilities	32	34	28	20	21	22	34
Total Current Liabilities	29	30	24	17	19	21	33
Accounts Payable	10	17	8.01	7.17	9.40	8.20	15
Accrued Expenses	18	9.35	13	6.98	6.98	10	15
Current Deferred Revenue	-	2.54	2.04	1.55	1.26	1.18	1.17
Other Current Liabilities	0.98	1.04	1.06	1.10	1.16	1.19	1.22
Total Noncurrent Liabilities	2.76	4.00	3.44	3.18	1.93	1.34	0.73
Noncurrent Deferred Revenue	-	1.77	1.50	1.52	0.87	0.59	0.29
Other Noncurrent Operating Liabilities	2.76	2.23	1.95	1.66	1.07	0.76	0.44
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	105	64	106	87	230	419	383
Total Preferred & Common Equity	105	64	106	87	230	419	383
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	105	64	106	87	230	419	383
Common Stock	595	633	708	714	923	1,145	1,159
Retained Earnings	-489	-568	-602	-627	-693	-726	-778
Accumulated Other Comprehensive Income / (Loss)	-0.54	-0.02	0.00	0.00	0.00	-0.07	1.33

This table displays calculated financial ratios and metrics derived from Praxis Precision Medicines' official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	249.53%
EBITDA Growth	-28.80%	42.24%	-52.67%
EBIT Growth	-27.91%	42.40%	-48.30%
NOPAT Growth	-28.48%	41.22%	-58.39%
Net Income Growth	-28.11%	42.40%	-48.30%
EPS Growth	-28.11%	73.17%	45.37%
Operating Cash Flow Growth	-48.56%	39.94%	-18.55%
Free Cash Flow Firm Growth	-49.44%	33.06%	-26.14%
Invested Capital Growth	2.85%	52.30%	-107.02%
Revenue Q/Q Growth	0.00%	26.66%	432.90%
EBITDA Q/Q Growth	7.70%	10.30%	-21.56%
EBIT Q/Q Growth	7.82%	10.39%	-21.06%
NOPAT Q/Q Growth	7.41%	9.75%	-22.04%
Net Income Q/Q Growth	7.52%	10.39%	-21.06%
EPS Q/Q Growth	7.52%	-22.80%	-27.63%
Operating Cash Flow Q/Q Growth	7.98%	4.26%	-32.42%
Free Cash Flow Firm Q/Q Growth	6.90%	1.03%	-26.87%
Invested Capital Q/Q Growth	-31.25%	18.83%	15.54%
Profitability Metrics	-	-	-
Gross Margin	0.00%	100.00%	100.00%
EBITDA Margin	0.00%	-5,018.31%	-2,191.87%
Operating Margin	0.00%	-5,164.41%	-2,340.29%
EBIT Margin	0.00%	-5,037.88%	-2,137.48%
Profit (Net Income) Margin	0.00%	-5,037.88%	-2,137.48%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-130.94%	-169.13%	-70.98%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-121.41%	-64.03%
Return on Assets (ROA)	0.00%	-121.41%	-64.03%
Return on Common Equity (ROCE)	-130.94%	-169.13%	-70.98%
Return on Equity Simple (ROE_SIMPLE)	-281.22%	-176.95%	-41.04%
Net Operating Profit after Tax (NOPAT)	-150	-88	-140
NOPAT Margin	0.00%	-3,615.08%	-1,638.20%
Net Nonoperating Expense Percent (NNEP)	-33.76%	-38.30%	-15.51%
Return On Investment Capital (ROIC_SIMPLE)	-	-126.97%	-31.45%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	1,718.59%	658.31%
R&D to Revenue	0.00%	3,545.81%	1,781.98%
Operating Expenses to Revenue	0.00%	5,264.41%	2,440.29%
Earnings before Interest and Taxes (EBIT)	-214	-123	-183
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-213	-123	-187
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.47	2.74	3.22
Price to Tangible Book Value (P/TBV)	1.47	2.74	3.22
Price to Revenue (P/Rev)	0.00	78.03	167.70
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	44.81	112.81
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.15	-1.25	-1.07
Leverage Ratio	1.25	1.39	1.11
Compound Leverage Factor	1.25	1.39	1.11
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	-10.07	-7.80	20.11
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	3.23	5.39	10.77
Quick Ratio	2.93	5.16	10.45
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-151	-101	-128
Operating Cash Flow to CapEx	-41,676.35%	-222,272.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.02	0.03
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	3.14	20.91
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-24	-12	-24
Invested Capital Turnover	0.00	-0.14	-0.48
Increase / (Decrease) in Invested Capital	0.72	13	-12
Enterprise Value (EV)	12	110	965
Market Capitalization	112	191	1,434
Book Value per Share	$1.62	$0.54	$23.90
Tangible Book Value per Share	$1.62	$0.54	$23.90
Total Capital	76	70	445
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-100	-81	-470
Capital Expenditures (CapEx)	0.44	0.05	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-24	-12	-26
Debt-free Net Working Capital (DFNWC)	76	69	367
Net Working Capital (NWC)	76	69	367
Net Nonoperating Expense (NNE)	64	35	43
Net Nonoperating Obligations (NNO)	-100	-81	-470
Total Depreciation and Amortization (D&A)	1.42	0.48	-4.65
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-497.30%	-301.01%
Debt-free Net Working Capital to Revenue	0.00%	2,825.13%	4,288.81%
Net Working Capital to Revenue	0.00%	2,825.13%	4,288.81%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($69.60)	($18.69)	($10.21)
Adjusted Weighted Average Basic Shares Outstanding	3.07M	6.59M	17.91M
Adjusted Diluted Earnings per Share	($69.60)	($18.69)	($10.21)
Adjusted Weighted Average Diluted Shares Outstanding	3.07M	6.59M	17.91M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	3.49M	13.24M	20.16M
Normalized Net Operating Profit after Tax (NOPAT)	-150	-88	-140
Normalized NOPAT Margin	0.00%	-3,615.08%	-1,638.20%
Pre Tax Income Margin	0.00%	-5,037.88%	-2,137.48%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.12%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Praxis Precision Medicines' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-36.90%	-54.29%	-35.47%	1,349.13%
EBITDA Growth	0.88%	29.45%	45.34%	42.85%	43.80%	34.51%	-5.95%	0.30%	-119.48%	-124.24%
EBIT Growth	1.69%	29.81%	45.49%	43.00%	43.95%	34.72%	-5.60%	4.77%	-110.74%	-118.32%
NOPAT Growth	1.08%	29.33%	44.67%	42.11%	42.39%	32.92%	-9.96%	-7.23%	-122.74%	-130.01%
Net Income Growth	1.70%	29.72%	45.49%	43.00%	43.95%	34.72%	-5.60%	4.77%	-110.74%	-118.32%
EPS Growth	4.00%	29.72%	45.49%	43.00%	43.95%	69.55%	73.16%	76.42%	-1.10%	19.61%
Operating Cash Flow Growth	-87.46%	35.78%	39.30%	45.44%	48.32%	17.17%	36.50%	12.61%	-18.46%	-135.20%
Free Cash Flow Firm Growth	-65.11%	-18.40%	-67.32%	-52.85%	28.39%	-8.35%	-0.72%	6.64%	-15.82%	-0.33%
Invested Capital Growth	-0.70%	2.85%	32.20%	29.62%	22.87%	52.30%	36.28%	21.12%	-98.95%	-107.02%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	14.35%	-40.08%	10.04%	-16.31%	-17.17%	-15.41%	2,371.19%
EBITDA Q/Q Growth	27.10%	6.33%	8.73%	8.31%	28.30%	-9.15%	-47.66%	13.72%	-57.83%	-11.52%
EBIT Q/Q Growth	26.99%	6.31%	9.03%	8.39%	28.21%	-9.12%	-47.16%	17.38%	-58.86%	-13.04%
NOPAT Q/Q Growth	26.66%	6.41%	8.11%	8.22%	27.01%	-8.97%	-50.64%	10.50%	-51.61%	-12.53%
Net Income Q/Q Growth	26.99%	6.31%	9.03%	8.39%	28.21%	-9.12%	-47.16%	17.38%	-58.86%	-13.04%
EPS Q/Q Growth	27.27%	6.31%	9.03%	8.39%	28.21%	-50.00%	30.39%	38.73%	-58.05%	-19.27%
Operating Cash Flow Q/Q Growth	21.48%	35.87%	-14.02%	4.97%	25.63%	-2.78%	12.59%	-30.79%	-0.81%	-104.08%
Free Cash Flow Firm Q/Q Growth	-45.96%	3.70%	-23.78%	12.15%	31.62%	-45.71%	-15.06%	18.57%	15.17%	-26.23%
Invested Capital Q/Q Growth	29.99%	-31.25%	12.42%	12.55%	23.27%	18.83%	-16.98%	-8.27%	-93.52%	15.54%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	0.00%	0.00%	-5,461.79%	-4,379.51%	-5,239.96%	-5,197.48%	-9,170.53%	-9,552.10%	-17,822.19%	-804.26%
Operating Margin	0.00%	0.00%	-5,577.01%	-4,476.31%	-5,452.14%	-5,399.22%	-9,718.33%	-10,500.84%	-18,819.54%	-856.97%
EBIT Margin	0.00%	0.00%	-5,483.89%	-4,393.34%	-5,263.25%	-5,219.03%	-9,177.03%	-9,153.22%	-17,188.74%	-786.27%
Profit (Net Income) Margin	0.00%	0.00%	-5,483.89%	-4,393.34%	-5,263.25%	-5,219.03%	-9,177.03%	-9,153.22%	-17,188.74%	-786.27%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-115.41%	-130.94%	-143.07%	-128.33%	-143.36%	-169.13%	-85.25%	-47.16%	-64.34%	-70.98%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	-22.17%	-40.98%	-83.48%	-125.78%	-115.50%	-56.43%	-105.50%	-23.55%
Return on Assets (ROA)	0.00%	0.00%	-22.17%	-40.98%	-83.48%	-125.78%	-115.50%	-56.43%	-105.50%	-23.55%
Return on Common Equity (ROCE)	-115.41%	-130.94%	-143.07%	-128.33%	-143.36%	-169.13%	-85.25%	-47.16%	-64.34%	-70.98%
Return on Equity Simple (ROE_SIMPLE)	-220.08%	0.00%	-283.50%	-148.53%	-158.57%	0.00%	-54.59%	-29.53%	-39.46%	0.00%
Net Operating Profit after Tax (NOPAT)	-31	-29	-27	-24	-18	-19	-29	-26	-40	-45
NOPAT Margin	0.00%	0.00%	-3,903.91%	-3,133.42%	-3,816.50%	-3,779.46%	-6,802.83%	-7,350.59%	-13,173.68%	-599.88%
Net Nonoperating Expense Percent (NNEP)	-5.91%	-6.46%	-7.00%	-6.79%	-6.02%	-8.16%	-6.22%	-2.31%	-4.73%	-5.05%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-27.94%	-	-	-	-10.05%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	1,942.90%	1,296.67%	1,864.10%	1,928.74%	3,557.54%	2,964.99%	5,051.66%	202.75%
R&D to Revenue	0.00%	0.00%	3,734.11%	3,279.64%	3,688.03%	3,570.49%	6,260.79%	7,635.85%	13,867.88%	754.23%
Operating Expenses to Revenue	0.00%	0.00%	5,677.01%	4,576.31%	5,552.14%	5,499.22%	9,818.33%	10,600.84%	18,919.54%	956.97%
Earnings before Interest and Taxes (EBIT)	-44	-41	-37	-34	-25	-27	-40	-33	-52	-59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-44	-41	-37	-34	-25	-27	-40	-34	-54	-60
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.98	1.47	0.66	0.68	2.53	2.74	3.52	1.69	2.67	3.22
Price to Tangible Book Value (P/TBV)	0.98	1.47	0.66	0.68	2.53	2.74	3.52	1.69	2.67	3.22
Price to Revenue (P/Rev)	0.00	0.00	62.06	48.78	113.77	78.03	368.02	399.54	636.60	167.70
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	61.45	44.81	257.18	154.57	380.42	112.81
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.09	-1.15	-1.21	-1.18	-1.17	-1.25	-1.12	-1.06	-1.09	-1.07
Leverage Ratio	1.15	1.25	1.32	1.28	1.27	1.39	1.19	1.10	1.11	1.11
Compound Leverage Factor	1.15	1.25	1.32	1.28	1.27	1.39	1.19	1.10	1.11	1.11
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-3.20	-5.11	-7.80	-4.67	-1.39	-4.18	19.92	17.70	16.17	20.96
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.57	3.23	3.16	5.31	6.15	5.39	11.27	17.30	10.96	10.77
Quick Ratio	4.27	2.93	2.87	5.09	6.02	5.16	11.04	17.06	10.86	10.45
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-31	-30	-37	-32	-22	-32	-37	-30	-26	-32
Operating Cash Flow to CapEx	-99,820.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.01	0.02	0.02	0.01	0.01	0.01	0.03
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.68	1.55	2.17	3.14	3.27	3.14	3.29	20.91
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-19	-24	-21	-19	-14	-12	-14	-15	-29	-24
Invested Capital Turnover	0.00	0.00	-0.03	-0.06	-0.12	-0.14	-0.13	-0.11	-0.07	-0.48
Increase / (Decrease) in Invested Capital	-0.13	0.72	10	7.86	4.25	13	7.75	3.94	-14	-12
Enterprise Value (EV)	-20	12	-43	-53	119	110	565	274	611	965
Market Capitalization	103	112	42	71	220	191	808	708	1,022	1,434
Book Value per Share	$2.31	$1.62	$1.23	$1.70	$0.67	$0.54	$17.35	$24.50	$21.55	$23.90
Tangible Book Value per Share	$2.31	$1.62	$1.23	$1.70	$0.67	$0.54	$17.35	$24.50	$21.55	$23.90
Total Capital	105	76	64	106	87	70	230	419	383	445
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-124	-100	-86	-124	-101	-81	-243	-434	-411	-470
Capital Expenditures (CapEx)	0.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-20	-24	-21	-19	-15	-12	-14	-16	-30	-26
Debt-free Net Working Capital (DFNWC)	103	76	64	105	87	69	193	336	327	367
Net Working Capital (NWC)	103	76	64	105	87	69	193	336	327	367
Net Nonoperating Expense (NNE)	13	12	11	9.84	6.77	7.41	10	6.44	12	14
Net Nonoperating Obligations (NNO)	-124	-100	-86	-124	-101	-81	-243	-434	-411	-470
Total Depreciation and Amortization (D&A)	0.31	0.30	0.15	0.11	0.11	0.11	0.03	-1.42	-1.91	-1.34
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	-3,123.87%	-1,291.05%	-753.11%	-497.30%	-656.31%	-891.19%	-1,859.50%	-301.01%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	9,441.58%	7,199.39%	4,479.04%	2,825.13%	8,793.17%	18,977.75%	20,385.48%	4,288.81%
Net Working Capital to Revenue	0.00%	0.00%	9,441.58%	7,199.39%	4,479.04%	2,825.13%	8,793.17%	18,977.75%	20,385.48%	4,288.81%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($14.40)	($201.00)	($10.65)	($7.35)	($2.70)	($4.08)	($2.84)	($1.74)	($2.75)	($3.28)
Adjusted Weighted Average Basic Shares Outstanding	3.05M	204.87K	3.54M	4.65M	9.04M	6.59M	13.90M	18.82M	18.88M	17.91M
Adjusted Diluted Earnings per Share	($14.40)	($201.00)	($10.65)	($7.35)	($2.70)	($4.08)	($2.84)	($1.74)	($2.75)	($3.28)
Adjusted Weighted Average Diluted Shares Outstanding	3.05M	204.87K	3.54M	4.65M	9.04M	6.59M	13.90M	18.82M	18.88M	17.91M
Adjusted Basic & Diluted Earnings per Share	$0.00	($201.00)	$0.00	$0.00	$0.00	($4.08)	$0.00	$0.00	$0.00	($3.28)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	3.14M	3.49M	4.14M	8.57M	8.57M	13.24M	17.11M	17.76M	18.64M	20.16M
Normalized Net Operating Profit after Tax (NOPAT)	-31	-29	-27	-24	-18	-19	-29	-26	-40	-45
Normalized NOPAT Margin	0.00%	0.00%	-3,903.91%	-3,133.42%	-3,816.50%	-3,779.46%	-6,802.83%	-7,350.59%	-13,173.68%	-599.88%
Pre Tax Income Margin	0.00%	0.00%	-5,483.89%	-4,393.34%	-5,263.25%	-5,219.03%	-9,177.03%	-9,153.22%	-17,188.74%	-786.27%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.11%	-0.12%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Praxis Precision Medicines' Financials

When does Praxis Precision Medicines's fiscal year end?

According to the most recent income statement we have on file, Praxis Precision Medicines' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Praxis Precision Medicines' net income changed over the last 2 years?

Praxis Precision Medicines' net income appears to be on a downward trend, with a most recent value of -$182.82 million in 2024, falling from -$214.03 million in 2022. The previous period was -$123.28 million in 2023.

What is Praxis Precision Medicines's operating income?

Praxis Precision Medicines's total operating income in 2024 was -$200.17 million, based on the following breakdown:

Total Gross Profit: $8.55 million
Total Operating Expenses: $208.72 million

How has Praxis Precision Medicines revenue changed over the last 2 years?

Over the last 2 years, Praxis Precision Medicines' total revenue changed from $0.00 in 2022 to $8.55 million in 2024, a change of 855,300,000.0%.

How much debt does Praxis Precision Medicines have?

Praxis Precision Medicines' total liabilities were at $37.66 million at the end of 2024, a 106.0% increase from 2023, and a 3.5% decrease since 2022.

How much cash does Praxis Precision Medicines have?

In the past 2 years, Praxis Precision Medicines' cash and equivalents has ranged from $61.62 million in 2022 to $215.37 million in 2024, and is currently $215.37 million as of their latest financial filing in 2024.

How has Praxis Precision Medicines' book value per share changed over the last 2 years?

Over the last 2 years, Praxis Precision Medicines' book value per share changed from 1.62 in 2022 to 23.90 in 2024, a change of 1,379.7%.

Related Companies

This page (NASDAQ:PRAX) was last updated on 4/19/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Praxis Precision Medicines (PRAX) Financials

Frequently Asked Questions About Praxis Precision Medicines' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Praxis Precision Medicines (PRAX) Financials

Annual Income Statements for Praxis Precision Medicines

Quarterly Income Statements for Praxis Precision Medicines

Annual Cash Flow Statements for Praxis Precision Medicines

Quarterly Cash Flow Statements for Praxis Precision Medicines

Annual Balance Sheets for Praxis Precision Medicines

Quarterly Balance Sheets for Praxis Precision Medicines

Annual Metrics and Ratios for Praxis Precision Medicines

Quarterly Metrics and Ratios for Praxis Precision Medicines

Frequently Asked Questions About Praxis Precision Medicines' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools